Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters


Cancer Drug Resistance is selected to be included in Emerging Sources Citation Index(ESCI)

Published on: 11 Aug 2022 Viewed: 1170

On August 10, 2022, Cancer Drug Resistance (CDR, 2578-532X (Online))  is selected to be included in Emerging Sources Citation Index (ESCI), which marks a significant milestone in the development of CDR.

The Emerging Sources Citation Index (ESCI) aims to extend the scope of publications in the Web of Science to include high-quality, peer-reviewed publications. It ensures that important research is visible in the Web of Science Core Collection. Thus, being included in the ESCI database is a passport to achieving a higher international stage. For CDR, it means that its academic standard and influence have been recognized by the international academic and publishing community; at the same time, CDR takes another step forward to becoming a world-class journal.

Up to now, CDR has been included in important international databases, such as ESCI, PMC, CAS, Scopus, etc. The Editorial Team would like to express sincere appreciation to all Editorial Board members, authors, reviewers, and readers for their continuous support of the journal. In the future, CDR Editorial Office will continue to follow the strict and standard peer-review rules to ensure high-quality publications and strive to develop CDR into a journal with more international influence.

Welcome to follow and contribute to CDR. CDR supports golden open access publishing. All articles are free to read and download.
Contact us:
Twitter: @cdrjournal
Linkedin: Cancer Drug Resistance

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties